<DOC>
	<DOCNO>NCT00111423</DOCNO>
	<brief_summary>The purpose study evaluate safety additional 28 week treatment pegsunercept subject complete treatment previous double-blind study ( 20000201 20000198 ) . In addition , study evaluate efficacy feasibility subject self-administration outpatient basis .</brief_summary>
	<brief_title>Evaluating Safety Extended Treatment With Pegsunercept ( PEG sTNF-RI ) Subjects With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subjects complete 24 week doubleblind treatment previous protocol ( 20000201 20000198 ) Females childbearing potential male must practice adequate contraception , judgement investigator , course study The subject legally acceptable representative must give informed consent participation study study specific procedure perform Greater 7day duration week 24 visit previous study first dose study Any medical disability condition ( e.g. , evidence clinically significant liver dysfunction , active infection require treatment systemic antiinfective agent ) would interfere assessment safety study material would compromise ability subject provide adequate inform consent Concurrent treatment investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Rheumatoid Arthritis , Inflammation</keyword>
	<keyword>Pegsunercept , PEG sTNF-RI</keyword>
	<keyword>Autoimmune , Amgen</keyword>
	<keyword>Clinical Trials</keyword>
</DOC>